Sihuan And Other Leading Chinese Drug Firms Could Get Boost From Current Meeting Of National People's Congress In Beijing
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Sihuan Pharmaceutical Holdings Group, based on the tropical Chinese island of Hainan, could see a sharp upward trajectory in earnings over the next three years as it continues to expand its product portfolio through acquisitions fueled by proceeds raised during its initial public offering and a government push to consolidate the Chinese pharmaceutical industry
You may also be interested in...
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
SHANGHAI - While Beijing is hosting China's National People's Congress this week to discuss and design its next Five-Year Plan, China's powerful National Development and Reform Commission announced another round of price cuts on antibiotics and cardiovascular drugs with an average price reduction of 21%, less than the rumored 30-40% cuts, but still a blow to Big Pharma
Chinese Premier, In Rare Online Chat, Pledges Higher Levels Of State Reimbursement For Medical Care And Insurance
BEIJING - In an almost-live online chat this week with China's cyber-citizenry, Premier Wen Jiabao vowed to strengthen China's social safety net, including upgraded medical services and insurance, while stating "every citizen should share the fruits of the reform and opening up drive.
China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March